We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+16.48%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11.7B
AUM Growth
+$1.25B
Cap. Flow
-$79.9M
Cap. Flow %
-0.68%
Top 10 Hldgs %
34.47%
Holding
156
New
27
Increased
33
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$208M
2
ACT.PRA
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
+$109M
3
BMY icon
Bristol-Myers Squibb
BMY
+$74.8M
4
BLUE
bluebird bio
BLUE
+$56.1M
5
CAH icon
Cardinal Health
CAH
+$54.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$191M
2
AGN
Allergan Inc
AGN
+$158M
3
MRK icon
Merck
MRK
+$149M
4
BIIB icon
Biogen
BIIB
+$113M
5
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$106M

Sector Composition

Rank Sector Weight
1 Healthcare 83.37%
2 Technology 0.15%
3 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WMGI
51
DELISTED
Wright Medical Group Inc
WMGI
$65.2M 0.56%
2,527,000
– –
BMY icon
52
CALL
Bristol-Myers Squibb
BMY
$130B
$64.5M 0.55%
1,000,000
+750,000
+300% +$47M
JNJ icon
53
Johnson & Johnson
JNJ
$646B
$61.7M 0.53%
613,000
+118,000
+24% +$12M
SIEN
54
DELISTED
Sientra, Inc.
SIEN
$61.1M 0.52%
318,531
– –
INFI
55
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$59.6M 0.51%
4,264,900
-472,000
-10% -$7.22M
MDT icon
56
PUT
Medtronic
MDT
$113B
$54.3M 0.46%
+695,707
New +$52.7M
NUVA
57
DELISTED
NuVasive, Inc.
NUVA
$49.3M 0.42%
1,072,000
– –
KYTH
58
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$47.5M 0.41%
947,900
+225,000
+31% +$9.44M
PRQR icon
59
ProQR Therapeutics
PRQR
$243M
$40.1M 0.34%
1,831,400
+2,000
+0.1% +$41.3K
XNPT
60
DELISTED
XENOPORT, INC.
XNPT
$39.5M 0.34%
5,546,100
– –
EXAS
61
DELISTED
Exact Sciences
EXAS
$39.2M 0.33%
1,778,000
– –
MRTX
62
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$37.1M 0.32%
1,267,000
+100,000
+9% +$2.35M
AFMD
63
DELISTED
Affimed
AFMD
$36.6M 0.31%
581,463
– –
CERS icon
64
Cerus
CERS
$577M
$34.6M 0.3%
8,307,727
+1,272,727
+18% +$6.52M
PTLA
65
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$32.3M 0.28%
850,700
– –
BHC icon
66
Bausch Health
BHC
$1.7B
$32.2M 0.27%
162,000
– –
HZNP
67
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$27.9M 0.24%
1,075,000
– –
UNH icon
68
UnitedHealth
UNH
$387B
$27.8M 0.24%
235,000
– –
TCRT icon
69
Alaunos Therapeutics
TCRT
$4.71M
$27.3M 0.23%
+16,918
New +$25.1M
FWP
70
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$27.2M 0.23%
137,229
– –
LOXO
71
DELISTED
Loxo Oncology, Inc
LOXO
$27.1M 0.23%
2,175,857
– –
LUMO
72
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$27M 0.23%
+54,811
New +$21.2M
RCPT
73
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$25.7M 0.22%
156,100
– –
ASND icon
74
Ascendis Pharma A/S
ASND
$16.6B
$25.1M 0.21%
+1,448,991
New +$26.3M
MRK icon
75
Merck
MRK
$326B
$23.3M 0.2%
424,440
-2,630,794
-86% -$149M
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2015 Portfolio in Review

As of Q1 2015, OrbiMed held 156 positions worth $11.7B, up 12% from $10.5B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q1 2015 filing shows 27 new, 33 increased, 24 reduced and 20 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 104,200 shares worth $105M. The largest sale was Vertex Pharmaceuticals, an estimated $191M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier, followed by Technology and Financials.

  • OrbiMed's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 104,200 shares worth $105M.
  • OrbiMed added most to Boston Scientific in Q1 2015, an estimated $208M increase.
  • OrbiMed's biggest Q1 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $191M.
  • OrbiMed fully exited Allergan Inc in Q1 2015, selling an estimated $158M.
  • OrbiMed's ten largest holdings make up 34% of its $11.7B portfolio in Q1 2015.
  • OrbiMed opened 27 new positions and closed 20 in Q1 2015.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $11.7B.

Based on OrbiMed's 13F filing for Q1 2015, filed 15 May 2015.